As of February 29, 2008, more than 44,000 of 47,000 eligible claimants have enrolled in the Program.  This constitutes over93% of all eligible claimants.  This enrollment percentage exceeds the 85% thresholds established in the settlement agreement   Merck retained a right to walk away from the Agreement unless 85% of eligible claimants alleging a heart attack, stroke, death or greater than 12 months Vioxx usage enrolled in the Program. While validation of the enrollments and supporting documentation is ongoing, it appears from current analysis that the 85% thresholds will not only be met but exceeded.  As a result, Merck’s right to walk away would be extinguished, and Merck obligated to pay $4.85 billion into a resolution fund from which to compensate qualified eligible claimants.